Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis

Can J Psychiatry. 2005 Jul;50(8):462-9. doi: 10.1177/070674370505000806.

Abstract

Objective: Response to typical antipsychotic medication has been associated with achieving a level of striatal dopamine D2 receptor occupancy in the range of 65% to 70%. We undertook this study to determine whether response to the atypical antipsychotic olanzapine occurs at lower levels of D2 receptor occupancy.

Method: Eighteen patients who presented with a first episode of psychosis were randomized to receive olanzapine 5 mg daily or haloperidol 2 mg daily in a double-blind design. We acquired positron emission tomography (PET) scans using the D2 ligand [11C]raclopride within the first 15 days of treatment to determine the percentage of D2 receptors occupied by the medication. According to response, dosage was then adjusted to a maximum dosage of 20 mg daily of either drug. PET scans were repeated after 10 to 12 weeks of treatment.

Results: At the first PET scan, the 8 olanzapine-treated patients had significantly lower D2 receptor occupancies (mean 63.4%, SD 7.3) than those observed in the 10 patients treated with haloperidol (mean 73.0%, SD 6.1). When patients were rescanned following dosage adjustment, mean D2 receptor occupancies were greater than 70% in both groups. D2 receptor occupancies did not differ significantly between the olanzapine-treated group (mean 72.0%, SD 5.7) and the haloperidol-treated group (mean 78.7%, SD 7.6).

Conclusions: These results suggest that, in patients being treated for a first episode of psychosis, olanzapine has its antipsychotic effect at approximately the same levels of D2 receptor occupancy as are achieved with low dosages of haloperidol.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antipsychotic Agents / administration & dosage*
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacokinetics
  • Benzodiazepines / administration & dosage
  • Benzodiazepines / adverse effects
  • Benzodiazepines / pharmacokinetics
  • Corpus Striatum / diagnostic imaging
  • Corpus Striatum / drug effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Haloperidol / administration & dosage*
  • Haloperidol / adverse effects
  • Haloperidol / pharmacokinetics
  • Humans
  • Male
  • Olanzapine
  • Positron-Emission Tomography*
  • Psychotic Disorders / diagnostic imaging
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / psychology
  • Raclopride
  • Receptors, Dopamine D2 / drug effects*
  • Schizophrenia / diagnostic imaging
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Receptors, Dopamine D2
  • Benzodiazepines
  • Raclopride
  • Haloperidol
  • Olanzapine